<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04259281</url>
  </required_header>
  <id_info>
    <org_study_id>GTX-102-001</org_study_id>
    <nct_id>NCT04259281</nct_id>
  </id_info>
  <brief_title>A Study of the Safety and Tolerability of GTX-102 in Children With Angelman Syndrome</brief_title>
  <acronym>KIK-AS</acronym>
  <official_title>A Phase 1/2 Open-label, Multiple-dose, Dose-escalating Clinical Trial of the Safety and Tolerability of GTX-102 in Pediatric Patients With Angelman Syndrome (AS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GeneTX Biotherapeutics, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ultragenyx Pharmaceutical Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GeneTX Biotherapeutics, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1/2, open-label, multiple-dose, dose-escalating study to evaluate the safety,
      tolerability, and plasma and cerebrospinal fluid (CSF) concentrations of GTX-102 in pediatric
      patients with Angelman syndrome. Approximately 20 patients (male and female) ≥ 4 and ≤ 17
      years of age with a genetically confirmed diagnosis of full maternal UBE3A gene deletion
      (within 15q11.2-q13 region) will be enrolled.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1/2, open-label, multiple-dose, dose-escalating study to evaluate the safety,
      tolerability, and plasma and CSF concentrations of GTX-102 in pediatric patients with AS.

      The study includes screening, baseline, treatment, and safety follow-up periods. Eligible
      patients who meet all of the inclusion criteria and none of the exclusion criteria and who
      successfully complete all screening and baseline assessments will be assigned to one of 5
      sequential dose cohorts. GTX-102 will be administered by intrathecal (IT) injection via
      lumbar puncture (LP) at Baseline followed by 3 subsequent IT injections on study Days 30, 58
      and 86. The procedure for IT administration of GTX-102 will performed by a clinician with
      experience in LP and anesthetic care will be directed by experienced anesthesiologists with a
      focus on patient safety and comfort. The total duration of study for each patient is
      anticipated to be approximately 6 months. An open-label extension (OLE) study will be
      conducted under a separate protocol where patients can receive continued treatment with
      GTX-102.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 24, 2020</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: incidence of adverse events</measure>
    <time_frame>Day 128 (end of study)</time_frame>
    <description>Number of patients with adverse events (AEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: incidence of serious adverse events</measure>
    <time_frame>Day 128 (end of study)</time_frame>
    <description>Number of patients with serious adverse events (SAEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: severity of adverse events</measure>
    <time_frame>Day 128 (end of study)</time_frame>
    <description>Severity of AEs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of GTX-102</measure>
    <time_frame>Day 2, Day 3, Day 4, Day 30, Day 58, Day 86, Day 128 (end of study)</time_frame>
    <description>Maximum drug concentration (Cmax)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pharmacodynamics of GTX-102</measure>
    <time_frame>Day 86</time_frame>
    <description>UBE3A protein levels in CSF</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory: Change in motor function by wearable device</measure>
    <time_frame>Day 128 (end of study)</time_frame>
    <description>Ambulation measured by wearable device</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory: Change in development</measure>
    <time_frame>Change from baseline to Day 128 (end of study) on total score</time_frame>
    <description>Developmental assessment by Bayley Scales of Infant/Toddler Development 4 (BSID-4)</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory: Change in communication</measure>
    <time_frame>Change from baseline to Day 128 (end of study) on total score</time_frame>
    <description>Observer Reported Communication Assessment (ORCA)</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory: Seizure frequency</measure>
    <time_frame>Day 128 (end of study)</time_frame>
    <description>Seizure frequency by diary</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory: Change in sleep</measure>
    <time_frame>Day 128 (end of study)</time_frame>
    <description>Assessment of sleep by diary</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory: Change in behaviors</measure>
    <time_frame>Day 128 (end of study)</time_frame>
    <description>Aberrant Behaviors Check List Community Version (ABC-C)</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory: Adaptive behaviors</measure>
    <time_frame>Change from baseline to Day 128 (end of study) on total score</time_frame>
    <description>Vineland Adaptive Behaviors Scale-3 (VABS-3)</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory: Global Clinical Status</measure>
    <time_frame>Day 128 (end of study)</time_frame>
    <description>Clinical Global Impression of Severity - Angelman syndrome version (CGI-S-AS)</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Angelman Syndrome</condition>
  <arm_group>
    <arm_group_label>GTX-102 Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GTX-102 Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GTX-102 Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GTX-102 Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GTX-102 Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose E</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GTX-102</intervention_name>
    <description>antisense oligonucleotide</description>
    <arm_group_label>GTX-102 Cohort 1</arm_group_label>
    <arm_group_label>GTX-102 Cohort 2</arm_group_label>
    <arm_group_label>GTX-102 Cohort 3</arm_group_label>
    <arm_group_label>GTX-102 Cohort 4</arm_group_label>
    <arm_group_label>GTX-102 Cohort 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent from parent(s) or legal guardian(s)

          -  Documented genetic confirmation of full maternal UBE3A gene deletion causing AS (e.g.
             DNA methylation testing with either a chromosomal microarray or FISH) in the region of
             15q11.2-q13 including class I, II or III).

          -  Age ≥ 4 to ≤ 17 years at screening

          -  Stable seizure control (defined as clinically stable with no changes in antiepileptic
             medications over the prior 1 month before screening visit, other than weight
             associated dose adjustments)

          -  Platelet count, prothrombin time (PT) / international normalized ratio (INR) and
             partial thromboplastin time (PTT) within normal limits

          -  Normal renal function with serum creatinine and spot urine protein within normal
             limits

          -  Normal hepatic function with total bilirubin, aspartate aminotransferase (AST),alanine
             aminotransferase (ALT) and alkaline phosphatase within normal limits

          -  Willing and able to comply with scheduled visits, drug administration plan, laboratory
             tests, study restrictions, and all study procedures LP.

          -  Able to tolerate the anesthetic regimen required for LP procedure

        Exclusion Criteria:

          -  Any change in medications (excluding antiepileptic drugs) or diet intended to treat
             symptoms of AS (e.g. sleeping aids, supplements, ketogenic or low-glycemic index diet,
             other) over the prior 3 months before screening.

          -  Inability to ambulate independently or with an assistive device or caregiver hand-hold

          -  Any bleeding or platelet disorder

          -  Any clinically significant (CS) cardiovascular, endocrine, hepatic, renal, pulmonary,
             gastrointestinal, neurologic, malignant, metabolic, psychiatric, or other condition
             that, in the judgment of the Investigator, will pose a safety risk, will make the
             patient unsuitable for participation in, and/or unable to complete the study
             procedures.

          -  Any laboratory abnormality, that, in the Investigator's opinion, could adversely
             affect the safety of the patient, make it unlikely that the course of treatment or
             follow up would be completed, or impair the assessment of study result

          -  Any active infection

          -  Bone, spine, bleeding, or other disorder that exposes the patient to risk of injury or
             unsuccessful lumbar puncture

          -  Drugs that increase the risk of bleeding (e.g. heparin, low molecular weight heparin,
             platelet inhibitors).

          -  Use of any investigational oligonucleotide in the past 6 months

          -  Any prior use of gene therapy

          -  Use of any investigational drugs in the past 6 months

          -  Any medical condition that would require intubation for the anesthesia procedure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Scott Stromatt, MD</last_name>
    <phone>206-225-6749</phone>
    <email>info@genetxbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brittany Murphy</last_name>
      <email>Brittany.Murphy@childrenscolorado.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rare Disease Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arvice Carroway</last_name>
      <email>arvice.carroway@rarediseaseresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haley Richter</last_name>
      <email>haley_e_richter@rush.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45299</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hanna Ingraham</last_name>
      <email>Hannah.Ingraham@cchmc.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 31, 2020</study_first_submitted>
  <study_first_submitted_qc>February 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2020</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angelman Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

